Cisplatin News and Research

RSS

New clinical trial seeks alternatives for head and neck cancer patients unable to use cisplatin

A physician-scientist at the University of Oklahoma is part of an international effort seeking new options for patients with head and neck cancer who cannot receive the standard chemotherapy drug cisplatin.

21 Feb 2025

AstraZeneca receives positive NICE recommendations for lung cancer treatment

AstraZeneca announced that this week it has received two positive recommendations from the National Institute for Health and Care Excellence (NICE) for the treatment of lung cancer patients across England and Wales.

25 Jan 2025

New clinical trial aims to extend survival for bile duct cancer patients

A new clinical trial, sponsored by UCL and UCLH, aims to extend survival for some patients with cancer in the biliary tract by treating them with therapies specifically tailored to the genetic profile of their tumor.

17 Jan 2025

Triple-drug chemo fails to improve survival in advanced biliary tract cancer

The results of a clinical trial led by researchers at the University of Arizona Health Sciences and published in the Journal of Clinical Oncology showed that chemotherapy combining three different types of drugs did not improve overall survival for patients with advanced stage, inoperable biliary tract cancers.

17 Jan 2025

ORACLE test enhances prediction of lung cancer outcomes

A new test, developed by researchers from UCL Cancer Institute and the Francis Crick Institute, can better predict lung cancer survival at the point of diagnosis, which could inform treatment decisions and potentially reduce the risk of the cancer returning or spreading.

13 Jan 2025

A large-scale tongue cancer organoid library for precision oncology

Oral cancer is an increasingly prevalent disease worldwide, with over 300,000 new cases diagnosed each year. Among oral cancers, tongue cancer (TC) is the most common type and often carries a poor prognosis. Surgery combined with chemoradiotherapy is one of the main lines of treatment for high-risk cases of TC.

9 Jan 2025

New test predicts lung cancer survival better than current standards

Researchers at the Francis Crick Institute, the UCL Cancer Institute and UCLH have shown that a test called ORACLE can predict lung cancer survival at the point of diagnosis better than currently used clinical risk factors.

9 Jan 2025

Dinuclear platinum(II) complexes could offer a more targeted approach to treating prostate cancer

Prostate cancer remains a global health challenge, ranking as the second most commonly diagnosed cancer among men.

16 Dec 2024

Research finds no change in mortality despite platinum chemotherapy shortage

During a shortage of the generic platinum chemotherapy drugs cisplatin and carboplatin that began in early 2023, there was no difference in mortality rates among patients with advanced cancer compared to the previous year, and prescription rates for the two drugs fell less than three percent overall - and 15.1 percent at the peak - according to an analysis published this week in the Journal of the National Cancer Institute by researchers from the University of Pennsylvania's Perelman School of Medicine and Penn Medicine's Abramson Cancer Center.

14 Dec 2024

PROSPECT-Lung trial aims to improve treatment for patients with resectable non-small cell lung cancer

The highly anticipated PROSPECT-Lung trial has officially opened, marking a significant step forward in the quest to improve treatment strategies for patients with resectable non-small cell lung cancer.

11 Dec 2024

New gold-based drug proves to be more potent than standard chemotherapy

A new gold-based drug can slow tumour growth in animals by 82% and target cancers more selectively than standard chemotherapy drugs, according to a study by Australian and Indian researchers.

27 Nov 2024

Cetuximab performs better than durvalumab in treating head and neck cancers

Head and neck cancers are the seventh most common type of cancer worldwide, according to the 2020 World Cancer Report. Smokers and drinkers, as well as those with HPV infections, are disproportionately affected.

22 Nov 2024

Targeting ferroptosis for overcoming chemoresistance in digestive tract tumors

The global burden of digestive tract tumors is profound, with these cancers accounting for nearly half of all malignant tumors worldwide.

8 Nov 2024

New drug WNTinib shows promise in treating pediatric liver cancer

A new drug called WNTinib can delay the growth of tumors and improve survival in hepatoblastoma, a type of liver cancer that occurs in young children.

22 Oct 2024

Study reveals complex role of polyploidy in cancer and treatment resistance

Polyploidy is a state where a cell contains more copies of the genetic material than the usual "diploid" cell, which contains two copies.

21 Oct 2024

New combination treatment authorized for unresectable urothelial cancer patients

Astellas Pharma Ltd. today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted authorization for PADCEV™ (enfortumab vedotin, an antibody-drug conjugate [ADC]) in combination with KEYTRUDA® (pembrolizumab, a PD-1 inhibitor) for the first-line treatment of adult patients with unresectable or metastatic urothelial cancer, who are eligible for platinum-containing chemotherapy.

18 Oct 2024

New compounds from fungi show promise in treating colorectal cancer

Novel chemical compounds from a fungus could provide new perspectives for treating colorectal cancer, one of the most common and deadliest cancers worldwide.

17 Oct 2024

Short course chemotherapy boosts survival rates in cervical cancer patients

Cervical cancer patients were significantly more likely to be alive and cancer-free after five years when given a short course of chemotherapy prior to chemoradiation, finds a clinical trial led by researchers from UCL and UCLH.

15 Oct 2024

Study illuminates the origin and progression of bladder cancer

How bladder cancer originates and progresses has been illuminated as never before in a study led by researchers at Weill Cornell Medicine and the New York Genome Center.

9 Oct 2024

Standard chemoradiation outperforms de-intensified treatments in HPV-associated oropharyngeal cancer

Researchers looking to de-intensify radiation treatments for people with early-stage, HPV-associated oropharyngeal cancer to prevent long-term side effects halted a large, randomized phase II/III trial after patients in the control arm reached a record high, two-year progression-free survival rate of 98%.

30 Sep 2024